A detailed history of High Point Advisor Group LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, High Point Advisor Group LLC holds 3,485 shares of VRTX stock, worth $1.57 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
3,485
Previous 4,428 21.3%
Holding current value
$1.57 Million
Previous $2.08 Million 21.93%
% of portfolio
0.1%
Previous 0.12%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$460.0 - $505.78 $433,780 - $476,950
-943 Reduced 21.3%
3,485 $1.62 Million
Q2 2024

Aug 08, 2024

BUY
$392.81 - $485.53 $198,761 - $245,678
506 Added 12.9%
4,428 $2.08 Million
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $136,168 - $148,990
334 Added 9.31%
3,922 $1.64 Million
Q4 2023

Mar 26, 2024

BUY
$343.0 - $410.68 $629,062 - $753,187
1,834 Added 104.56%
3,588 $1.46 Million
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $412,119 - $513,132
1,754 New
1,754 $511,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $199,528 - $223,289
-1,100 Closed
0 $0
Q2 2021

Jul 29, 2021

BUY
$187.49 - $221.1 $206,239 - $243,210
1,100 New
1,100 $222,000
Q3 2020

Nov 06, 2020

SELL
$255.65 - $303.1 $641,170 - $760,174
-2,508 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $23,224 - $30,467
103 Added 4.28%
2,508 $718,000
Q1 2020

May 01, 2020

BUY
$199.77 - $247.81 $350,796 - $435,154
1,756 Added 270.57%
2,405 $649,000
Q1 2020

Apr 27, 2020

SELL
$199.77 - $247.81 $508,614 - $630,924
-2,546 Reduced 79.69%
649 $2.41 Million
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $307,746 - $413,337
-1,846 Reduced 36.62%
3,195 $747,000
Q1 2019

May 08, 2019

SELL
$163.73 - $194.7 $9,168 - $10,903
-56 Reduced 1.1%
5,041 $858,000
Q4 2018

Feb 20, 2019

BUY
$151.91 - $192.21 $24,305 - $30,753
160 Added 3.24%
5,097 $952,000
Q2 2018

Aug 20, 2018

BUY
$145.72 - $169.96 $719,419 - $839,092
4,937 New
4,937 $864,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track High Point Advisor Group LLC Portfolio

Follow High Point Advisor Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Point Advisor Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Point Advisor Group LLC with notifications on news.